Back To Top

Tip: To quickly find your search term on this page, press "Ctrl" + "f" on your keyboard (Command + "f" on a Mac) and use the find bar.
Lapatinib Catalog#: A-1319
         Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
LBH-589 Catalog#: A-1025
         LBH-589 is a highly potent deacetylase inhibitor shown to impede multiple pathways implicated in cancer associated with cutaneous T-cell lymphoma and other challenging malignancies.
LBW-242 Catalog#: A-1420
         LBW242 is a Smac mimetic, and potent IAP inhibitor.
LCL-161 Catalog#: A-1147
         Promoting cancer cell death by deactivating inhibitor of apoptosis proteins (IAPs)
LDK-378 Catalog#: A-1189
         LDK-378 is an ALK inhibitor.
Ledipasvir Acetone Catalog#: A-9003
         Ledipasvir (GS5885) acetone is an inhibitor of the hepatitis C virus NS5A protein, which is an experimental drug for the treatment of hepatitis C.
LEE-011 Catalog#: A-1277
         LEE011 is a new oral drug designed to inhibit the activity of an enzyme known as CDK4/6.
LEQ-506 Catalog#: A-1276
         LEQ506 is an orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity.
Levetiracetam Catalog#: A-9039
         Levetiracetam is a pyrrolidine with antiepileptic activity.
LGH-447 Catalog#: A-1512
         LGH447 is an orally available pan-PIM protein kinase inhibitor with potential antineoplastic activity.
LGK-974 Catalog#: A-1400
         LGK-974 is a selective porcupine inhibitor targeting Wnt signaling in cancer.
Linagliptin Catalog#: A-9041
         Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
LOR-253 Catalog#: A-1421
         LOR-253 HCl is the hydrochloride salt of a small molecule inhibitor of human metal-regulatory transcription factor 1 (MTF-1) with potential antitumor activity.
LOXO-101 Catalog#: A-9048
         LOXO-101 is an orally bioavailable, potent, ATP-competitive inhibitor of TRKA, TRKB, and TRKC.
LOXO-195 Catalog#: A-6100
         LOXO-195 is a selective A2A inhibitor.
Lucitanib Catalog#: A-1364
         Lucitanib, also known as E-3810, is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity.
Lucitanib(E-3810) Catalog#: A-1268
         E-3810 is a potent dual inhibitor of VEGFR and FGFR.
LXS-196 Catalog#: A-6075
         LXS-196 is a selective PKC inhibitor.
LY-2090314 Catalog#: A-1239
         LY-2090314 is a potent GSK3-beta inhibitor in clinical trials.
LY-2157299 Catalog#: A-1616
         LY-2157299 CAS.700874-72-2
LY-2228820 Catalog#: A-1265
         LY2228820 is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM.
LY-2334737 Catalog#: A-1702
         LY2334737 is an oral gemcitabine prodrug in which gemcitabine is linked to valproic acid via an amide bond, enabling it to bypass hydrolysis in enterocytes and portal circulation, thereby avoiding the extensive first pass metabolism that occurs with unmodified gemcitabine.
LY-2523355 Catalog#: A-1271
         LY-2523355 is an allosteric inhibitor of Eg5 which selectively inhibits bipolar mitotic spindle formation.
LY-2603618 Catalog#: A-1240
         LY-2603618 is a potent CHK1 inhibitor in clinical trials.
LY-2606368 Catalog#: A-1703
         LY2606368 is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity.
LY-2608204 Catalog#: A-1959
         LY2608204 is a potent activator of glucokinase (GK) with EC₅₀ of 42 nM. Potential antidiabetic agent to treat type 2 diabetes.
LY-2780301 Catalog#: A-1237
         LY-2780301 is a potent p70S6K/AKT dual inhibitor in clinical trials
LY-2784544 Catalog#: A-1170
         LY2784544 is a small molecule selective mutant JAK2 kinase inhibitor.
LY-2835219 Catalog#: A-1407
         LY-2835219 is a CDK 4/6 dual Inhibitor.
LY-2874455 Catalog#: A-1198
         LY2874455 is a Novel FGF/FGFR Inhibitor.
LY-2875358 Catalog#: A-1313
         anti-c-MET monoclonal antibody LY2875358
LY-2886721 Catalog#: A-1958
         LY2886721 is a BACE inhibitor used for the treatment of Alzheimer's Disease. Phase 1/2.
LY-294002 Catalog#: A-6111
         LY-294002 is a selective PI3K inhibitor.
LY-2940680 Catalog#: A-1248
         LY-2940680 is a Hedgehog inhibitor in clinical trials.
LY-3007113 Catalog#: A-1411
         LY-3007113 is a p38 MAPK Inhibitor.
LY-3009120 Catalog#: A-1317
         LY03009120 is a potent and selective pan-Raf inhibitor.
LY-3023414 Catalog#: A-1704
LY-3039478 Catalog#: A-1705
LY-3154567 Catalog#: A-1963
LY-3200882 Catalog#: A-6084
         LY-3200882 is a selective TGFBR1 inhibitor.
LY-3214996 Catalog#: A-6069
         LY-3214996 is a selective ERK1/2 inhibitor.
LY-450139 Catalog#: A-1262
         Semagacestat (LY450139) is a novel gamma-secretase inhibitor.
LY-900009 Catalog#: A-1238
         LY-900009 is a potent Notch inhibitor in clinical trials.
LY2801653 Catalog#: A-1182
         LY2801653 is a c-Met inhibitor.
LY411575 Catalog#: A-1615
         LY411575 CAS:209984-57-6

*Note: These products are for research purposes only, not for human consumption.